BRAF-V600E 突变型乳头状颅咽管瘤对 BRAF 和 MEK 抑制剂联合治疗反应显著。
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
作者信息
Roque Ashley, Odia Yazmin
机构信息
Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Department of Neurology, Columbia University Medical School, New York, NY, USA.
出版信息
CNS Oncol. 2017 Apr;6(2):95-99. doi: 10.2217/cns-2016-0034.
Abstract
We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.
摘要
我们报告了一名患有BRAF-V600E突变型乳头状颅咽管瘤的患者，在其无法切除的肿瘤对放疗无效后，成功接受了BRAF（达拉非尼，每日两次，每次150毫克）和MEK（曲美替尼，每日2毫克）抑制剂联合治疗。系列脑部磁共振成像（MRI）和正电子发射断层显像（PET）显示肿瘤明显缩小，神经功能逐渐改善，并出现永久性全垂体功能减退。
相似文献
1
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
CNS Oncol. 2017 Apr;6(2):95-99. doi: 10.2217/cns-2016-0034.
2
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Acta Neurochir (Wien). 2017 Nov;159(11):2217-2221. doi: 10.1007/s00701-017-3311-0. Epub 2017 Sep 16.
3
Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
J Clin Pharm Ther. 2022 Jun;47(6):826-831. doi: 10.1111/jcpt.13600. Epub 2022 Jan 12.
4
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
J Natl Cancer Inst. 2015 Oct 23;108(2). doi: 10.1093/jnci/djv310. Print 2016 Feb.
5
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF Mutated Papillary Thyroid Cancer: Two Case Reports.
Thyroid. 2017 Sep;27(9):1201-1205. doi: 10.1089/thy.2017.0106.
6
TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
Clin Neurol Neurosurg. 2020 Sep;196:106059. doi: 10.1016/j.clineuro.2020.106059. Epub 2020 Jun 30.
7
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
8
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Clin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28.
9
BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study.
Eur J Endocrinol. 2024 Aug 5;191(2):251-261. doi: 10.1093/ejendo/lvae091.
10
Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
World Neurosurg. 2023 Dec;180:e117-e126. doi: 10.1016/j.wneu.2023.08.137. Epub 2023 Sep 6.
引用本文的文献
1
Comparative analysis of clinical features, methylation and immune microenvironment in pediatric and adult papillary craniopharyngiomas: results from a multicenter study.
Sci Rep. 2025 Jul 28;15(1):27422. doi: 10.1038/s41598-025-12662-8.
2
Targeted therapy of papillary craniopharyngioma.
Med Oncol. 2025 Jul 22;42(8):367. doi: 10.1007/s12032-025-02920-0.
3
Endoscopic Endonasal Approach for Residual and Recurrent Craniopharyngioma after Transcranial Approach: A Multi-institutional Experience.
J Neurol Surg B Skull Base. 2024 May 3;86(3):295-302. doi: 10.1055/a-2301-3867. eCollection 2025 Jun.
4
Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review.
Neurol Med Chir (Tokyo). 2025 May 15;65(5):217-229. doi: 10.2176/jns-nmc.2024-0246. Epub 2025 Mar 21.
5
The spectrum of radiation therapy options for craniopharyngioma: a systematic review.
J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-05001-4.
6
Advances in the Management of Craniopharyngioma: A Narrative Review of Recent Developments and Clinical Strategies.
J Clin Med. 2025 Feb 9;14(4):1101. doi: 10.3390/jcm14041101.
7
Targeted treatment for craniopharyngioma.
J Neurooncol. 2025 May;172(3):503-513. doi: 10.1007/s11060-025-04942-0. Epub 2025 Feb 14.
8
Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma.
Endocr Oncol. 2024 Dec 19;4(1):e240024. doi: 10.1530/EO-24-0024. eCollection 2024 Jan 1.
9
Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review.
Front Oncol. 2024 Nov 27;14:1464362. doi: 10.3389/fonc.2024.1464362. eCollection 2024.
10
Practical application of precision oncology in adult onset craniopharyngiomas.
Front Endocrinol (Lausanne). 2024 Nov 20;15:1488958. doi: 10.3389/fendo.2024.1488958. eCollection 2024.
本文引用的文献
1
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Acta Neuropathol Commun. 2016 Feb 29;4:20. doi: 10.1186/s40478-016-0287-6.
2
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
J Natl Cancer Inst. 2015 Oct 23;108(2). doi: 10.1093/jnci/djv310. Print 2016 Feb.
3
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
4
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
5
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
Pituitary. 2016 Oct;19(5):544-6. doi: 10.1007/s11102-015-0663-4.
6
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Nat Genet. 2014 Feb;46(2):161-5. doi: 10.1038/ng.2868. Epub 2014 Jan 12.
7
High frequency of BRAF V600E mutations in ameloblastoma.
J Pathol. 2014 Apr;232(5):492-8. doi: 10.1002/path.4317. Epub 2014 Jan 31.
8
Inhibition of mutated, activated BRAF in metastatic melanoma.
N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.
9
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up.
Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409. doi: 10.1111/j.1365-2265.2005.02231.x.
10
Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.
Am J Pathol. 2002 Dec;161(6):1997-2001. doi: 10.1016/s0002-9440(10)64477-x.
Zotero 插件